Wednesday, April 25, 2018

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Human Clinical Study of Its High Absorption TurboCBD Capsules

  • Study will measure the cardiovascular and cognitive health effects of patented DehydraTECH, its disruptive delivery technology
  • Data generated will help company’s development of next-generation cannabinoid product formulations
  • Chris Bunka, CEO, and John Docherty, president, to present at the ‘Next Generation Nicotine Delivery USA 2018’ conference in Atlanta on April 24 and 25
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has started a human clinical study in Europe on the health effects of its high absorption TurboCBD™ capsules. LXRP, a drug delivery platform innovator, will be conducting the study to evaluate the cardiovascular and cognitive health effects of its patented DehydraTECH™ technology, the company announced (http://nnw.fm/SHcM5).
The study will measure the impact of the TurboCBD capsules on vascular function and cognitive performance improvement. The same DehydraTECH technology used in this study was utilized in the company’s recent rodent-based nicotine-absorption study. The two studies exhibit the wide applicability of LXRP’s proprietary drug delivery platform, the company said.
Based in British Columbia, Canada, LXRP out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.
The company will present on April 24 and 25 in Atlanta the results of its recent ingestible nicotine absorption study. At the ‘Next Generation Nicotine Delivery USA 2018’ conference, LXRP’s Chris Bunka, CEO, and John Docherty, president, will speak (http://nnw.fm/PYQi8).
Recently, LXRP conducted a lab study on animals that evaluated DehydraTECH technology as an alternative nicotine delivery method. Top line results showed that it might have potential as a possible nicotine replacement therapy.
Depending on results of the European human study, a second phase clinical study on the elderly may be conducted in later 2018, LXRP said.
For more information, visit the company’s website at www.LexariaBioscience.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)